Outlook Therapeutics' (OTLK) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK - Free Report) in a report published on Friday morning, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

Several other brokerages have also recently issued reports on OTLK. BTIG Research upgraded Outlook Therapeutics from a neutral rating to a buy rating and set a $50.00 price target on the stock in a research report on Wednesday, March 27th. Guggenheim upgraded shares of Outlook Therapeutics from a neutral rating to a buy rating and set a $40.00 price target on the stock in a research report on Thursday, January 25th. Capital One Financial restated an overweight rating on shares of Outlook Therapeutics in a research report on Friday, February 16th. Brookline Capital Management upgraded shares of Outlook Therapeutics from a hold rating to a buy rating and set a $31.40 target price on the stock in a report on Thursday, January 25th. Finally, Chardan Capital raised shares of Outlook Therapeutics from a neutral rating to a buy rating and set a $60.00 target price for the company in a research note on Thursday, February 15th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Outlook Therapeutics currently has a consensus rating of Moderate Buy and a consensus target price of $46.43.

Outlook Therapeutics Trading Up 6.1 %

OTLK stock traded up $0.45 during trading on Friday, hitting $7.78. The company had a trading volume of 185,220 shares, compared to its average volume of 484,092. The firm has a market capitalization of $101.22 million, a price-to-earnings ratio of -0.68 and a beta of 0.28. The business has a 50 day moving average of $8.43 and a 200 day moving average of $8.48. Outlook Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $40.60.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.20. As a group, equities analysts predict that Outlook Therapeutics will post -2.99 EPS for the current year.

Hedge Funds Weigh In On Outlook Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gables Capital Management Inc. boosted its position in Outlook Therapeutics by 132.3% during the 3rd quarter. Gables Capital Management Inc. now owns 154,500 shares of the company's stock worth $34,000 after acquiring an additional 88,000 shares during the period. Scotia Capital Inc. lifted its position in shares of Outlook Therapeutics by 420.9% in the third quarter. Scotia Capital Inc. now owns 338,439 shares of the company's stock worth $75,000 after purchasing an additional 273,463 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Outlook Therapeutics during the first quarter worth approximately $3,723,000. Institutional investors and hedge funds own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.